BioCryst Pharma revenues up 96% in Q4

• BioCryst Pharmaceuticals (NASDAQ:BCRX -17.6%) Q4 results: Revenues: $9M (+95.7%); Operating Loss: ($8.2M) (+52.3%); Net Loss: ($4.5M) (+75.1%); Loss Per Share: ($0.06) (+76.0%).
• 2016 results: Revenues: $26.4M (-45.3%); Operating Loss: ($48.6M) (-23.4%); Net Loss: ($55.1M) (-28.1%); Loss Per Share: ($0.75) (-27.1%); Quick Assets: $63.6M (-35.9%).
• 2017 Guidance: Net Operating Cash Use: $30M - 50M; Operating Expenses: $53M - 73M.